New blood tests, liquid biopsies, may transform cancer care

A new type of blood test is starting to transform cancer treatment, sparing some patients the surgical
and needle biopsies long needed to guide their care.

The tests, called liquid biopsies, capture cancer cells or DNA that tumors shed into the blood, instead
of taking tissue from the tumor itself. A lot is still unknown about the value of these tests, but many
doctors think they are a big advance that could make personalized medicine possible for far more people.

They give the first noninvasive way to repeatedly sample a cancer so doctors can profile its genes,
target drugs to mutations, tell quickly whether treatment is working, and adjust it as the cancer
Two years ago, these tests were rarely used except in research. Now, several are sold, more than a dozen
are in development, and some doctors are using them in routine care.
Gurpaul Bedi had one for colon cancer that spread to his lungs. About 10 percent of patients with
metastatic colon cancer at the University of Texas MD Anderson Cancer Center now get liquid biopsies.

"I think it’s wonderful," said Bedi, who lives in Atlanta and goes to Houston for his care.
"A lung biopsy, many doctors told me, is not easy."
In Philadelphia, a liquid biopsy detected Carole Linderman’s breast cancer recurrence months before it
normally would have been found.
"Had this test not been available, we may not have known I had cancer on my spine until symptoms
showed up," which may have been too late for good treatment, she said.
The huge potential for these tests is clear. The problem: There are no big, definitive studies to show
they help patients, how accurate they are, which type is best or who should get them and when.
Still, patients do better when drugs are matched to their tumors, and liquid biopsies may give a
practical way to do that more often.
"I’m really excited about all of this," said Dr. Razelle Kurzrock, a University of California,
San Diego cancer specialist. "I spent most of my life giving drugs that were useless to
people" because there was no good way to tell who would benefit or quickly tell when one wasn’t
working, she said. "This is so much better."
The tests are mostly used when a tissue biopsy can’t easily be done, when the cancer’s original site
isn’t known, or when drugs have stopped working and doctors are unsure what to try next, said Dr. Scott
Kopetz, a colon cancer specialist at MD Anderson. The tests are catching on "faster than I
anticipated," he said.
At Philadelphia’s Thomas Jefferson University, Dr. Massimo Cristofanilli has used them on about 120
breast cancer patients, including two dozen like Linderman with a high risk of recurrence.
A tissue biopsy typically samples one section of a tumor, and tumors can vary widely, with different
genes and hormones active in different parts, he said. Also, cancer that has spread often differs from
the original site, and tumors change rapidly in response to treatment.
With a tissue biopsy, "our treatments lag behind and they’re still based on limited
information," Cristofanilli said. With a liquid biopsy, "the power of this test has been to
really find out how the disease changes, even in a short period of time."
Early versions looked for whole tumor cells in blood. Newer ones look for free-floating cancer DNA,
enabling gene profiling to see what mutations drive the cancer. Kopetz and Cristofanilli use one from
Guardant Health Inc. of Redwood City, California, that has been sold in the U.S. since June 2014 and in
parts of Europe and Asia.
Many companies are working on similar tests including Sequenom, a San Diego biotech that already sells
one for prenatal screening, using fetal DNA in maternal blood. Many companies tried prenatal screening
with fetal cells but it didn’t work, said chief science officer Dirk van den Boom. "Cell-free DNA
really was the breakthrough" that enabled wide use, and the same could happen with these cancer
tests, he said.
Whether liquid biopsies will be cost-effective is unknown. Guardant’s test costs $5,400; some insurers
cover it for certain types of patients. Gene profiling from a tissue biopsy costs about the same. The
promise of liquid biopsies is that they can be done periodically to monitor care, but more tests means
more cost.
They may save other costs, though. A traditional lung biopsy is thousands of dollars. Money could be
saved by skipping cancer drugs that ultimately don’t work; many cost $10,000 to $15,000 a month.
With cell-free DNA tests, even doctors in rural areas can offer precision medicine because they can ship
a blood sample to a lab. "We think that’s the future," said Dr. Charles Baum, a former Pfizer
cancer drug chief who now heads Mirati Therapeutics, a San Diego biotech company developing
gene-targeting drugs
Many studies suggest that liquid biopsy results largely mirror those from tissue ones, and sometimes find
more mutations. A study Kopetz presented in April at an American Association for Cancer Research meeting
found the blood tests detected cancer mutations in the vast majority of 105 colorectal cancer patients.
For 37 percent of them, doctors thought a drug could target a mutation that was found.
Still, no big studies show that liquid biopsies give better care or extend lives. Without that proof, how
much they will be used by doctors and covered by insurers remains to be seen.
A San Diego company, Trovagene, is working on an even faster, easier liquid biopsy — a test to detect
tumor DNA in urine. One scenario: a patient collects a urine sample every day for a week after starting
a new drug and ships them to a lab.
"In as little as three to five days, you can observe dramatic changes" that suggest a response
to treatment, said Trovagene’s chief executive, Antonius Schuh.
Work on this test is still very early.
Ultimately, liquid biopsies might offer a way to screen for cancer besides the mammograms, colonoscopies
and other methods used now. That raises even more questions, including when to call something
"cancer" and whether it needs treatment if there are only abnormal cells in the blood.
"Why does there have to be a tumor? The tumor is the symptom. The disease is the DNA," Schuh
Marilynn Marchione can be followed at

Copyright 2015 The Associated Press. All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.